GRAIL vs Proscia Concentriq
Agilent announced on October 13, 2026 that it will acquire Proscia for up to $270M, made up of $240M in cash at closing and up to $30M in earnout, with closing expected early in Agilent's fiscal 2027. Concentriq AP-Dx has K230839 from February 2024 and K261380 from August 2026, and Proscia's release says the later one adds the Leica Aperio GT 450 DX, cloud deployment and a PCCP. Proscia announced SOC 2 Type II in December 2025, and it says 16 of the top 20 pharma companies use the platform.
For Galleri, GRAIL says an FDA advisory panel voted in favor on benefit versus risk on September 23, 2026, and the PMA is under review. The randomized NHS-Galleri trial missed its primary endpoint.
Concentriq goes to labs and research groups under a signed contract. Galleri reaches patients through a clinician's prescription, which is not a purchase a pathology lab makes.
Pathology · Reviewed November 2, 2026
GRAIL
by GRAIL
Galleri blood test for multi-cancer early detection, sold as a CLIA lab test. Not FDA cleared or approved.
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
When to pick each one
Proscia Concentriq
- Concentriq AP-Dx has two 510(k)s
- SOC 2 Type II announced December 2025
- Image management plus AI apps in one platform
Score
Each row shows points earned of points available under the published rubric.
GRAIL
28of 100
Proscia Concentriq
40of 100
| Dimension | GRAIL | Proscia Concentriq | Difference |
|---|---|---|---|
| FDA clearance | 0 / 18 | 18 / 18 | -18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 8.4 / 21 | 0 / 21 | +8.4 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 0 / 7.8 | +7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 0 / 5 | 2.5 / 5 | -2.5 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
GRAIL
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price verified. |
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Evidence
GRAIL
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names GRAIL.
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | GRAIL | Proscia Concentriq |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.